Role of p53 assessment in management of Barrett's esophagus

Digestive Diseases and Sciences

Volumn 44, Issue 4, 1999, Pages 659-667

  Kubba, A K ^a,b   Poole, N A ^a   Watson, A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Hope Hospital ^*  (United Kingdom)

Author keywords

Barrett's esophagus; p53 gene

Indexed keywords

PROTEIN P53;

BARRETT ESOPHAGUS; CELL PROLIFERATION; DNA CONTENT; DYSPLASIA; ESOPHAGUS MUCOSA; GENE MUTATION; HUMAN; INTESTINE MUCOSA; MITOSIS INDEX; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 0032890830     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026608319881     Document Type: Review

References (77)

1. 1. Blot WJ, Devesa SS, Kneller RW, et al: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287-1289, 1991
2. 2. Haggitt RC: Adenocarcinoma in Barrett's oesophagus: a new epidemic? Human Pathol 23:475-6, 1992
3. 3. Clark GWB, Ireland AP, DeMeester TR: Dysplasia in Barrett's oesophagus: Diagnosis, surveillance and treatment. Dig Dis 14:213-227, 1996
4. 4. Jones DR, Davidson AG, Summers CL, et al: Potential application of p53 as an intermediate biomarker in Barrett's oesophagus. Ann Thorac Surg 57:598-603, 1994
5. 5. Naef AP, Savary M, Ozzello L, Pearson FG: Columnar lined lower oesophagus. An acquired lesion with malignant predisposition. Report of 140 cases of Barrett's oesophagus with 12 adenocarcinomas. Ann Thorac Surg 13:543-551, 1972
6. 6. Barrett N: Chronic peptic ulcer of the oesophagus and oesophagitis. Br J Surg 38:175-82, 1950
7. 7. Spechler SJ, Robbins AH, Rubins HB, et al: Adenocarcinoma and Barrett's oesophagus. Gastroenterology 87:927-933, 1984
8. 8. Jaskiewicz K, Louw J, Anichkov N: Barrett's oesophagus: Mucin composition, neuroendocrine cells, cellular proliferation and differentiation. Anticancer Res 14:1907-1912, 1994
9. 9. Overholt B, Panjehpour M, Tefftellar E, Rose M: PDT for treatment of early adenocarcinoma in Barrett's oesophagus. Gastrointest Endosc 39:73-76, 1993
10. 10. Reid BJ, Blount PL, Rubin CE, et al: Flow cytometric and histological progression to malignancy in Barrett's oesophagus: Prospective endoscopic surveillance of a cohort. Gastroenterology 102:1212-1219, 1992
11. 11. Polkowski W, Van Lanschot JJB, Tenkate FJW, et al: The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol 4:163-171, 1995
12. 12. Altorki NK, Sunagawa M, Little AG, Skinner DB: Hígh grade dysplasia in the columnar lined oesophagus. Am J Surg 161:97-99, 1991
13. 13. Schnell T, Sontag S, Chejfec G, et al: High grade dysplasia in Barrett's oesophagus: A report of experience with 43 patients. Gastroenterology 96:A452, 1989
14. 14. Younes M, Lebovitz RM, Lechago LV, et al: p53 protein accumulation in Barrett's metaplasia, dysplasia and carcinoma: A follow-up study. Gastroenterology 105:1637-42, 1993
15. 15. Wright TA, Gray MR, Morris AI, et al: Cost effectiveness of detecting Barrett's cancer. Gut 39(4):574-9, 1996
16. 16. Achkar E, Carey W: The cost for surveillance of adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol 83:291-294, 1988
17. 17. McKinley MJ, Budman DR, Gruenberg D, et al: DNA content in Barrett's oesophagus and esophageal malignancy. Am J Gastroenterol 82:1012-1015, 1987
18. 18. Krishnadath KK, Tilanus HW, van Blankenstein M, Hop WC, Teijgeman R, Mulder AH, Bosman FT, van Dekken: Accumulation of genetic abnormalities during neoplastic progression in Burret's esophagus. Cancer Research 55:1971-1976, 1995
19. 19. Ohgaki H, Hard GC, Hirota N, et al: Selective mutation of codens 204 and 213 of the p53 gene in rat tumours induced by alkylating N-nitrosocompounds. Cancer Res 52:2995-2998, 1992
20. 20. Jankowski J, Jonkowski RF, Wormsley KG: Oesophageal carcinoma: The need for screening. Eur J Cancer Prev 3:5-15, 1993
21. 21. Nowell PC: The clonal evolution of tumour cell populations. Science 194:23-28, 1976
22. 22. Lane DP, Crawford LV: T antigen is bound to a host protein in SV 40 transformed cells. Nature 278:261-263, 1979
23. 23. Isobe M, Emanuel BS, Givol D: Localisation of gene for human p53 tumour antigen to band 17p13. Nature 320:84-85, 1986
24. 24. Tjian R: Molecular machines that control genes. Sci Am 00:54-61, 1995
25. 25. Fazeli A, Steen RG, Dickinson SL, et al: Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas. Proc Natl Acad Sci USA 94:10199-10204, 1997
26. 26. Blount PL, Galipeau PC, Sanchez CA, et al: p53 is frequently mutated in Barrett's metaplasia of the intestinal type. Cancer Epidemiol Biomarkers Prev 5:559-565, 1996
27. 27. Roth JA: The cell and molecular biology of oesophageal carcinoma. Chest Surg Clin North Am 4(2):205-216, 1994
28. 28. Levine AJ: Tumour suppressor genes. Bioassays 12:60-66, 1990
29. 29. Krishnadath KK, Van Blankenstein M, Tilanus W: Prognostic value of p53 in Barrett's oesophagus. Eur J Gastroenterol Hepatol 7:81-84, 1995
30. 30. Oren M, Maltzman W, Levine AJ: Posttranslational regulation of the 54K cellular tumour antigen in normal and transformed cells. Mol Cell Biol 1:101-110, 1981
31. 31. Levine DS: Barrett's oesophagus and p53. Lancet 344:212-213, 1994
32. 32. Greenblatt MS, Bennett WP, Hollstein MC, Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cancer aetiology and molecular pathogenesis. Cancer Res 54:2995-2998, 1994
33. 33. Iggo R, Gatter K, Bartek J, et al: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675-679, 1990
34. 34. Laurent-Puig P, Flejou J-F, Fabre M, et al: Overexpression of p53: A rare event in a large series of white patients with hepatocellular carcinomas. Hepatology 16:1171-5, 1992
35. 35. Jankowski J, Coghill G, Hopwood D, et al: Oncogenes and oncosuppressor genes in adenocarcinoma or the oesophagus. Gut 32:A1205-6, 1991
36. 36. Filipe MI, Jankowski J: Growth factors and oncogenes in Barrett's oesophagus and gastric metaplasia. Endoscopy 25(suppl):637-641, 1993
37. 37. Wagata T, Shibagaki I, Imamura M, et al: Loss of 17p, mutation of the p53 gene and overexpression of p53 protein in oesophageal squamous cell carcinomas. Cancer Res 53:846-50, 1993
38. 38. Casson AG, Mukhopadhyay T, Cleary KR, et al: p53 gene mutation in Barrett's epithelium and oesophageal cancer. Cancer Res 51:4495-9, 1991
39. 39. Blount PI, Ramel S, Raskind WH, et al. 17p allelic deletions and p53 protein over-expression in Barrett's adenocarcinoma. Cancer Res 51:5482-6, 1991
40. 40. Wyndford-Thomas D: p53 in tumour pathology: Can we trust immunocytochemistry? J Pathol 166:329-330, 1992
41. 41. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991
42. 42. Krishnadath KK, Tilanus HW, Van Blankstein M, et al: Accumulation pf p53 protein in normal, dysplastic and neoplastic Barrett's oesophagus. J Pathol 175:175-180, 1995
43. 43. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250:1233-1238, 1990
44. 44. Rice TW, Goldblum JR, Falk GW, et al: p53 immunoreactivity in Barrett's metaplasia, dysplasia and carcinoma. J Thorac Cardiovasc Surg 108:1132-7, 1994
45. 45. Lu X, Park SH, Thompson TC, Lane DP: Ras-induced hyperplasia occurs with mutation of p53 but activated ras and myc together can induce carcinoma without p53 mutation. Cell 70:153-161, 1992
46. 46. Greenblatt MS, Bennett WP, Hollstein MC, Harris CC: Mutations in the p53 tumour suppressor gene: Clues to cancer aetiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
47. 47. Ramel S, Reid BJ, Sanchez CA, et al: Evaluation of p53 protein expression in Barrett's oesophagus by two parameter flow cytometry. Gastroenterology 102:1220-1228, 1992
48. 48. Rodriques NR, Rowan A, Smith MEF, et al: p53 mutations in colorectal eancer. Proc Natl Acad Sci USA 87:7555-7559, 1990
49. 49. Baetek J, Bartkova J, Vojtesek B, et al: Patterns of the expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer 46:839-844, 1990
50. 50. Flejou JF, Muzeau F, Potet F, et al: Overexpression of the p53 tumour suppressor gene product in oesophageal and gastric carcinomas. Pathol Res Pract 190:1141-1148, 1994
51. 51. Flejou JF, Potet F, Muzeau F, et al: Overexpression of p53 protein in Barrett's syndrome with malignant transformation. Clin Pathol 46:330-333, 1993
52. 52. Flejou JF, Paraf F, Potet F, et al: p53 protein expression in Barrett's adenocarcinoma: A frequent event with no prognostic significance. Histopathology 24:487-489, 1994
53. 53. Symmans PJ, Linehan JM, Brito MJ, Filipe MI: p53 expression in Barrett's oesophagus, dysplasia and adenocarcinoma using antibody DO-7. J Pathol 173:221-226, 1994
54. 54. Roth JA: Molecular surgery for cancer. Arch Surg 127:1298-1302, 1992
55. 55. Campomenosi P, Conio M, Bogliolo M, et al: p53 is frequently mutated in Barrett's metaplasia of the intestinal type. Cancer Epidemiol Biomarkers Prev 5:559-565, 1996
56. 56. Neshat K, Sanchez CA, Galipeau PC, et al: p53 mutations in Barrett's adenocarcinoma and high grade dysplasia. Gastroenterology 106:1589-1595, 1994
57. 57. Li AGK, Gaunt M, Reynolds JV, et al: p53 immunohistochemistry identifies at risk patients with Barrett's oesophagus. The Surgical Research Society 10th Tripartite meeting, Nottingham, July 1997, Abstract 129
58. 58. Gleeson CM, Sloan JM, McGuigan JA, et al: Base transitions at CpG dinucleotide in the p53 gene are common in oesophageal adenocarcinoma. Cancer Res 55:3406-3411, 1995
59. 59. Wang Y, You M, Reynolds SH, et al: Mutational activation of the cellular harvey ras oncogene in rat esophageal pappilomas induced by methylbenzylnitrosamine. Cancer Res 50:1591-1595, 1990
60. 60. Swift A, Risk JM, Kingsnorth AN, Wright TA, et al: Frequent loss of heterozygosity on chromosome 17 at 17q11.2-q12 in Barrett's adenocarcinoma. Br J Cancer 71:995-998, 1995
61. 2/tetraploid) populations and progression to aneuploidy in Barrett's oesophagus. J Natl Acad Sci 93:7081-7084, 1996
62. 62. Reid BJ: Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 20:817-834, 1991
63. 63. Blount PL, Meltzer SJ, Yin J, et al: Clonal ordering of 17p and 5q allelic losses in Barrett's dysplasia and adenocarcinoma. Proc Natl Acad Sci USA 90:3221-3225, 1993
64. 64. Blount PL, Galipeau PC, Sanchez CA, Neshat K, et al: 17p allelic losses in diploid cells of patients with Barretts oesophagus who develop aneuploidy. Cancer Res 54:2292-2295, 1994
65. 65. Jankowski J, Coghill G, Hopwood D, Wormsley KG: Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 33:1033-1038, 1992
66. 66. Moore JH, Lesser EJ, Erdody DH, et al: Intestinal differentiation and p53 gene alterations in Barrett's oesophagus and oesophageal adenocarcinoma. Int J Cancer 56:487-493, 1994
67. 67. Casson AG, Munolopoulos B, Troster M, et al: Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive oesophageal cancer. Am J Surg 167:52-57, 1994
68. 68. Sauter ER, Keller SM, Erner SM: p53 correlates with improved survival in patients with esophageal adenocarcinoma. J Surg Oncol 58:269-273, 1995
69. 69. Hamelin R, Flejou JF, Muzeau F, et al: TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's oesophagus. Gastroenterology 107:1012-1018, 1994
70. 70. Hameeteman W, Tytgat GNJ, Houthoff HJ, et al: Barrett's oesophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 96:1249-56, 1989
71. 71. Jankowski J: Flow cytometric assessment of regulatory peptides in Barrett's mucosa. Gastroenterology 102:1121, 1992 (letter)
72. 72. Bennett WP: p53 alterations in progenitor lesions of the bronchus, oesophagus, oral cavity and colon. Cancer Det Prev 19(6):503-511, 1995
73. 73. Ireland AP, Clark GWB, DeMeester TR: Barrett's oesophagus: The significance of p53 in clinical practice. Ann Surg 225(1):17-30, 1997
74. 74. Krishnadath KK, Tilanus HW, Alers JC, et al: Detection of genetic changes in Barrett's adenocarcinoma and Barrett's oesophagus by DNA in situ hybridization and Immunohistochemistry. Cytometry 15:176-184, 1994
75. 75. Iannettoni MD, Lee SS, Bonnell, Sell TL, Whyte RI, Orringer MD, Beer DG: Detection od Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53. Ann Thorac Surg 62:1460-1465, 1996
76. 76. Liang Y, Esteve A, Martel-Planche G, Takahashi S, et al: p53 mutations in oesophageal tumors from high-incidence areas of China. Int J Cancer: 61:611-614, 1995
77. 77. Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D: Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut 35(6):764-768, 1994